TYK2 and Crohn disease: Although currently available therapeutic armamentarium resulting in somewhat durable remission in patents with ulcerative colitis, the treatment goal of corticosteroid-free clinical remission was hardly achieved with biologic and small-molecule therapies targeting TNF-α, 4β7 integrin, JAK, S1P, TYK2, etc.55Although the effect on small bowel lesions remain unclear, risankizumab represents a promising and favorable option for patients with Crohn's disease who still have unmet needs.56